Slide 1: 1
1
Slide 2: Table of Content
Table of Content SpectraCure in Brief Vision and Mission Historical Timeline Market Overview Treatment Method Clinical Study Business Model Looking Forward Investment Case Management & Board of Directors
Slide 3: SpectraCure – Enabling Better Prostate Cancer Treatment
SpectraCure – Enabling Better Prostate Cancer Treatment • SpectraCure is a medical technology company focused on developing and commercialising a new medical device for treating localised prostate cancer. » The company originates from a research team at Lund University, which began research on Photo
Slide 4: SpectraCure – Cure Cancer and Improve Quality of Life
SpectraCure – Cure Cancer and Improve Quality of Life Vision Mission Strategy SpectraCure wants to transform the SpectraCure’s strategy rests SpectraCure is confident that the landscape of cancer treatments. By on three core pillars: fusion of medical technology and combining the proven method of PD
Slide 5: Track-Record of Achieved Milestones, 2022–2024
Track-Record of Achieved Milestones, 2022–2024 Q4, 2022 Q4, 2022 Q2, 2023 Q4, 2023 Q1, 2024 Q4, 2024 SpectraCure signed an Memorial Sloan Kettering SpectraCure was The data and safety SpectraCure submitted the Established a LOI-agreement with Cancer Centre in New awarded its second EU monitoring boa
Slide 6: Prostate Cancer - Increasing Globally and Occurring at Younger Ages
Prostate Cancer - Increasing Globally and Occurring at Younger Ages Geographic distribution, Prostate Cancer, in 20224 • Prostate cancer is the second most common cancer in males. Africa: ~ 7 percent • Approximately 1 in 8 men will face a prostate cancer diagnosis in their lifetime, corresponding to
Slide 7: Primary and Recurrent Prostate Cancer
Primary and Recurrent Prostate Cancer 70 Percent 20 Percent of the prostate cancer cases are of patients treated with radiation primary prostate cancer.1 therapy suffers from relapsed disease.2 Primary Prostate Cancer Recurrent Prostate Cancer • Common treatment alternatives today for primary prosta
Slide 8: Growth in Prostate Cancer Therapeutics - Key Market Drivers
Growth in Prostate Cancer Therapeutics - Key Market Drivers 1 2 3 Increasing Prevalence of Innovative Screening Tech Increased Importance of Quality of Life Prostate Cancer Globally • The geriatric population is expected • It has been established that early • Traditional prostate cancer treatment to
Slide 9: Patented PDT Solution for Prostate Cancer Treatment
Patented PDT Solution for Prostate Cancer Treatment SpectraCure’s Treatment Method in Summary Focal Therapy – Targeted, Minimally Invasive Treatment • SpectraCure’s system employs Photodynamic Therapy • Traditional treatments target the entire prostate, for the treatment of the prostate tumour. lead
Slide 10: SpectraCure’s Solution - Consisting of Three Components
SpectraCure’s Solution - Consisting of Three Components Three Component Solution 1. Software - IDOSE® • Dose planning platform • High precision dose delivery, preventing over- and underexposure and thereby ensuring full treatment without damaging healthy tissue 2. Hardware • Laser unit, facilitating
Slide 11: Step-by-Step Treatment Process
Step-by-Step Treatment Process 1 2 3 4 The patient is given Needles are inserted into the The fibres deliver the IDOSE® tailors the verteporfin, which is a drug tumour with ultrasound calculated light dose and treatment based on the that makes the tissue guidance. IDOSE calculates ® simultaneously s
Slide 12: Revolutionising Prostate Cancer Care Options
Revolutionising Prostate Cancer Care Options Impact on Quality of Life Maintained Quality of Life Current treatments can cause significant Potential to empower patients to maintain a side effects, impacting patients' quality of 1 1 higher quality of life, addressing the specific life. issues that ha
Slide 13: Clinical Studies with Prominent Hospitals
Clinical Studies with Prominent Hospitals Princess Margaret Cancer Center • The initial focus was a clinical study addressing prostate cancer recurrence after radiotherapy, aiming to recruit patients from a highly motivated group facing limited University College London Hospital treatment options. S
Slide 14: Comprehensive and Global Patent Coverage
Comprehensive and Global Patent Coverage SpectraCure holds a significant patent portfolio with seven patent families totalling eleven granted patents. The basic patents have been approved in, among others, Europe, USA, China, and Japan. SpectraCure has three ongoing patent applications, two of which
Slide 15: SpectraCure’s Clinical Studies
SpectraCure’s Clinical Studies Study in Study in Recurrent Prostate Cancer Primary Prostate Cancer • A clinical trial on recurrent prostate cancer, recruiting patients • A clinical trial for primary prostate cancer. from a highly motivated group with limited treatment options. • The initiated trial
Slide 16: Mapping the Progress: Safety and Efficacy Studies
Mapping the Progress: Safety and Efficacy Studies 2024 2025 2026 2027 2028 2029 Phase 2b: Safety and efficacy study Evaluation of treatment Study on recurrent prostate cancer Study results reported Phase 3 study • Collaboration agreement for joint research • Fast-tracking or Orphan Drug Status to •
Slide 17: Recurring Revenue in Every Treatment
Recurring Revenue in Every Treatment One-time Cost Recurring Revenue Diverse Business Model Driven by Recurring Revenue and Economies of Scale Q-PRO® Treatment Package The laser unit and dosage platform will be sold as one Sales of the treatment package, consisting of sterile product. disposable equ
Slide 18: Long- and Short-Term Objectives
Long- and Short-Term Objectives Short Term Long Term Finalise Phase 2 of the clinical study for treatment of recurrent Find industrial partners for collaboration regarding Phase 3 of prostate cancer. the clinical study for treatment of recurrent prostate cancer. Conduct the Phase 1/2 clinical study
Slide 19: Delivering Greater Quality of Life in the Cancer Therapeutics Markets
Delivering Greater Quality of Life in the Cancer Therapeutics Markets Potential to Develop Treatment for More Cancer Diagnoses The treatment system has the potential to be suitable for treating several types of internal solid tumours, such as breast cancer. A New Treatment Option A Real Clinical Nee
Slide 20: An Experienced and Dedicated Management Team
An Experienced and Dedicated Management Team Masoud Khayyami Henrik Ljung Johannes Swartling Kristina Holst Acting CEO since 2023 CFO since 2018 CTO since 2009 Head of Clinical Affairs since 2022 Education: Ph.D. in technical Education: MBA, Lund University. Education: Ph.D. in physics, Lund Educati
Slide 21: A Board of Directors with Extensive Industry Expertise
A Board of Directors with Extensive Industry Expertise Jörgen Wennberg Masoud Khayyami Tomas Kramar Chairman of the Board since 2022 Board Member since 2022 Board Member since 2022 Education: Financial education, the Education: Ph.D. in technical Education: M.Sc. Chemical Merchant institute. chemist
Slide 22: A Board of Directors with Extensive Industry Expertise
A Board of Directors with Extensive Industry Expertise Homer Pien Jesper Freij Katarina Svanberg Board Member since 2021 Board Member since 2022 Board Member since 2003 Education: PhD in computer science, Education: MBA, Lund University. Education: M.D., Ph.D. Northeastern University, and MS Managem
Slide 23: Thank you
Thank you Contact information Email info@spectracure.com Phone +46 (0)70 936 74 12 Website www.spectracure.com